Medivation
Medivation was a San Francisco-based biopharmaceutical company (founded 2003, delisted) that developed small-molecule therapeutics for serious diseases before being absorbed into a larger multi-therapeutic biopharma platform.
- Company typePrivate
- Founded2003
- HeadquartersSan Francisco, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Medivation does
Medivation, Inc. was a San Francisco-based biopharmaceutical company founded in 2003 that focused on the rapid development of small-molecule therapeutics for serious diseases. The company operated with an employee base in the 501-1,000 range and was originally listed on NASDAQ under the ticker MDVN. Medivation's commercial and scientific profile centered on small-molecule drug discovery, development, and eventual commercialization of treatments for high-need therapeutic areas.
Medivation historically relied on a pipeline-driven business model: identifying small-molecule drug candidates, advancing them through clinical development, securing regulatory approval, and commercializing approved products. The 2008 funding event with Plough Penny Partners in the input represents one of the recorded capital-formation events in Medivation's independent history. As a clinical-stage to commercial biopharma, customer segments would have been specialty providers and their patients in the indications targeted by Medivation's portfolio.
Medivation is currently delisted and is no longer an independent operating company; it was absorbed into a major biopharmaceutical platform, with its assets, pipeline, and commercial operations integrated into the acquirer's broader multi-therapeutic-area franchise spanning oncology, internal medicine, inflammation and immunology, and vaccines. Standalone financial signals (revenue, ARR, segment splits) are not available in the provided source material.
Medivation firmographics
Firmographics- Name
- Medivation
- Website
- https://medivation.com
- Company type
- Private
- Founded year
- 2003
- Headcount range
- 501–1,000 employees
- Short description
- Medivation was a San Francisco-based biopharmaceutical company (founded 2003, delisted) that developed small-molecule therapeutics for serious diseases before being absorbed into a larger multi-therapeutic biopharma platform.
- Ownership category
- akta.pro rank
Medivation industry classification
Industry- Product category
- Specialty Biopharmaceuticals / Small Molecule Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
- akta.pro secondary industries
- Nephrology & Urology Pharmaceuticals (HLAIAAAM), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where Medivation is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Medivation business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Revenue generated from branded pharmaceutical products across multiple therapeutic areas including oncology, inflammation and immunology, vaccines, and internal medicine. Products are sold through multiple channels including direct-to-consumer and professional healthcare channels.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Pfizer RxPathways patient assistance program |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels6 records
Medivation product offering
Product offeringCore offering
Medivation is a biopharmaceutical company that focuses on the rapid development of small molecule drugs to treat serious diseases. The company built its offering on proprietary medicinal chemistry and clinical development capabilities, advancing branded therapeutics from discovery through commercialization, with revenue generated from pharmaceutical product sales across serious-disease indications.
Differentiator
Problem solved
Functional benefit
Products and services
- Small molecule therapeutics for serious diseases Proprietary small molecule drug candidates developed and advanced by Medivation for the treatment of serious diseases, intended for use by physicians and patients in specialty care settings.
Companies that use Medivation
Customer profileSegments4 records
Ideal customer profiles2 records
Medivation technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Medivation partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Patient Advocacy OrganizationscorePfizer partners with patient advocacy organizations for patient engagement and advocacy efforts, supporting patients throughout their healthcare journey.
- Healthcare ProfessionalscorePfizer works with healthcare professionals through PfizerPro portal, providing resources, product information, and collaboration opportunities in research and development.
- Research and Business Development PartnerscorePfizer engages in research partnerships and business development collaborations to advance pharmaceutical research and expand therapeutic capabilities.
- Pfizer CentreOnecorePfizer CentreOne is a strategic partnership unit within Pfizer focused on contract manufacturing and development services for complex pharmaceuticals.
- Suppliers and Business-to-Business PartnersminorPfizer collaborates with suppliers and B2B partners for manufacturing, supply chain, and business operations support.
Scale indicators4 records
Recent moves4 records
Expansion highlights4 records
Medivation competitors and assessment
Company assessmentBroad incumbents
- Bristol-Myers Squibb: Oncology-heavy global biopharma with significant urology and serious-disease exposure; a broadly comparable incumbent against which to benchmark Medivation's pipeline and commercial model.
- Bayer: Major oncology/urology incumbent with Nubeqa (darolutamide) competing in non-metastatic castration-resistant prostate cancer; similar small-molecule, serious-disease focus makes Bayer a structurally comparable peer to Medivation.
- Pfizer: Acquired Medivation in 2016 and is the parent/strategic owner; operates the broadest oncology and small-molecule pipeline overlapping Medivation's mandate and serves as both an integrator and a benchmark for scale.
- Merck & Co. Major oncology and vaccines player with small-molecule capabilities and prostate cancer exposure (e.g., Keytruda combinations); relevant incumbent peer for serious-disease pipeline benchmarking.
- AstraZeneca: Global biopharma with a heavy oncology franchise (including prostate cancer assets) and growing small-molecule pipeline; comparable on therapeutic-area overlap and serious-disease mandate.
- Novartis: Global biopharma with deep oncology and serious-disease presence including urologic cancers; comparable broad incumbent against which Medivation's pipeline economics can be judged.
- Johnson & Johnson (Innovative Medicine): Large incumbent in oncology and urology with prostate cancer franchises (e.g., Erleada) that directly compete with Xtandi; a meaningful comparable for evaluating Medivation's commercial positioning in oncology/urology.
Emerging players
- Arvinas: Clinical-stage targeted protein degrader company with oncology programs, including prostate cancer; smaller and earlier-stage than Medivation but overlapping in novel small-molecule approaches to serious cancers.
Direct peers
- Exelixis: Mid-sized oncology-focused biopharma developing small molecule drugs (cabozantinib) for prostate, kidney, and other serious cancers; closely comparable in size, therapeutic focus, and small-molecule modality.
- Astellas Pharma: Co-developer of Xtandi (enzalutamide) with Medivation for prostate cancer; the most directly comparable peer given shared development, commercialization, and royalty relationship on Medivation's flagship oncology/urology asset.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights5 records
Customer concentration
Medivation social profiles
Digital presenceMedivation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medivation leadership team
Management profileNumber of profiles
Medivation funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medivation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medivation
What does Medivation do?
Medivation is a biopharmaceutical company that focuses on the rapid development of small molecule drugs to treat serious diseases. The company built its offering on proprietary medicinal chemistry and clinical development capabilities, advancing branded therapeutics from discovery through commercialization, with revenue generated from pharmaceutical product sales across serious-disease indications.
When was Medivation founded?
Medivation was founded in 2003. It employs 501 to 1,000 people.
Where is Medivation based?
Medivation is headquartered in San Francisco, United States, in the North America region.
How does Medivation make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Medivation's main competitors?
Broad incumbents on record are Bristol-Myers Squibb, Bayer, Pfizer, Merck & Co., AstraZeneca, Novartis and Johnson & Johnson (Innovative Medicine). Arvinas is listed as an emerging player. Direct peers are Exelixis and Astellas Pharma.
Does Medivation have an API?
No public API is recorded for Medivation.
What industry is Medivation in?
Medivation's product category is Specialty Biopharmaceuticals / Small Molecule Therapeutics. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAIAAAM, Nephrology & Urology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.